drug

ustekinumab biosimilar

Marketedupdated 2mo ago

by Accord Biopharma Inc

Approved

community read0 votes

indications

investigational

IBD (Crohn's + UC)

all catalysts(6)

approval · 6

News(0)

no news has mentioned this drug yet

brand

Imuldosa

generic

ustekinumab-kfce

MOA

12.1 Mechanism of Action Ustekinumab products are human IgG1κ monoclonal antibodies that bind with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation. In in vitro models, ustekinumab products were shown to disrupt IL-12 and IL-23 mediated signaling and cytokine cascades by disrupting the interaction of these cytokines with a shared cell-surface receptor chain, IL-12Rβ1. The cytokines IL-12 and IL-23 have been implicated as important contributors to the chronic inflammation that is a hallmark of Crohn’s disease and ulcerative colitis. In animal models of colitis, genetic absence or antibody blockade of the p40 subunit of IL-12 and IL-23, the target of ustekinumab products, was shown to be protective.

indication

Psoriatic Arthritis

phase

marketed

ustekinumab biosimilar

indications

all catalysts(6)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside

Trials studying ustekinumab biosimilar